Today’s Forbes CFO newsletter focuses on Aradhana Sarin’s journey from treating patients to becoming what she calls a ...

AstraZeneca's (AZN) revenue hit a record high in the second quarter, driven by cancer drug sales and growth in the US market.

Uncertainty about pharmaceutical tariffs continues to loom over the pharmaceutical industry, with some companies committing ...

Aradhana Sarin, AstraZeneca CFO, says the company is making a significant commitment to the U.S., explaining that the ...

AstraZeneca has dropped the lead candidate from its $200 million buyout of Neogene Therapeutics as part of a wider cell ...

Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

Earlier this month, fellow European drugmaker Roche Holding AG said it was looking into direct sales to bypass players like ...

Today’s Forbes Daily newsletter covers Trump’s Fed chair candidates, Palantir’s rising share price, RFK cancels vaccine funding, GOP pushes for more on Epstein and more.

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

AstraZeneca PLC ( NASDAQ: AZN) Q2 2025 Earnings Conference Call July 29, 2025 9:00 AM ET ...

British-Swedish pharmaceutical company AstraZeneca announced a $50 billion investment in the U.S. this week, with the Trump administration claiming some credit due to its tariff policy and Presiden… ...